Ibrance 125 mg Capsule

Description

Ibrance 125 mg Capsule contains Palbociclib, an advanced targeted therapy used in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. It works by blocking the activity of proteins called CDK4 and CDK6 (Cyclin-Dependent Kinases), which are essential for cancer cell growth and division. By inhibiting these kinases, Ibrance helps slow or stop the progression of cancer.

Ibrance is often prescribed in combination with hormonal therapy such as letrozole or fulvestrant, offering an effective option for postmenopausal women or patients with disease progression after prior endocrine treatment.

Key Benefits:

• Proven targeted treatment for HR+, HER2-negative breast cancer

• Slows down cancer cell growth and spread

• Oral capsule for convenient at-home use

• Enhances results when combined with hormonal therapy

Dosage & Administration:
The usual recommended dose is 125 mg once daily for 21 consecutive days, followed by 7 days off treatment (one complete 28-day cycle).
Take the capsule with food, swallowed whole — do not crush, chew, or open it. Always follow your oncologist’s exact instructions.

Possible Side Effects:
Common side effects may include fatigue, nausea, diarrhea, loss of appetite, mouth sores, low white blood cell count (neutropenia), or hair thinning. Regular blood tests are required to monitor your blood cell levels during treatment.

Storage:
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Warning:
Ibrance 125 mg Capsule is a prescription-only anti-cancer medicine. Use under the supervision of a qualified oncologist. Not recommended during pregnancy or breastfeeding.